Oxford BioMedica intends to raise £8.1m to provide the group with working capital to fund its development pipeline and manufacturing-related technology. The group anticipates a number of business catalysts over the course of the next twelve months, all of which have previously been disclosed. Oxford BioMedica has sufficient cash resources into H2 2016 and will need to raise further equity finance during 2016. We will update our forecasts and valuation in due course. Our recommendation is currently under review.
